Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

This study measures how dupilumab (an injectable biologic used to treat moderate-to-severe asthma) affects the ability of the lungs to clear mucus and debris — a process called mucociliary clearance — in people with Type 2 (allergic/eosinophilic) asthma. **You may be eligible if...** - You are over 18 with moderate-to-severe Type 2 asthma - Your lung function is below 90% of predicted (FEV1 < 90%) - You are on medium-to-high-dose inhaled corticosteroids (500 mcg/day or more of fluticasone equivalent) - You have documented airway reversibility (your breathing improves with a bronchodilator, or you have a positive challenge test) **You may NOT be eligible if...** - Your asthma is mild or not of the Type 2 (eosinophilic/allergic) variety - You are a smoker or have significant COPD - You have a recent lung infection or recent change in asthma medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.